Consent given pursuant to sections 14 and 14A to the importation and supply of the therapeutic goods specified by Generic Health

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate the provision of therapeutic goods, including medicines, within Australia. This Act aims to ensure that therapeutic goods available in Australia are of acceptable quality, are safe, and have appropriate labelling. The Therapeutic Goods Administration (TGA), a department under the Commonwealth of Australia, administers this Act. In addressing potential gaps in compliance due to transitional changes in regulatory requirements, the Act includes provisions for consents that allow for the temporary importation and supply of therapeutic goods that do not fully comply with certain standards until a specified date. The example given concerns a consent granted to Generic Health Pty Ltd for the supply of specific batches of pharmaceutical products that do not fully meet the new labelling requirements introduced on 12 December 2015, but only until 30 June 2017. The consent is conditional upon adherence to previously approved labelling and is intended to provide a temporary solution while the regulated entities adjust to the new legislative requirements. This legislative framework facilitates a balance between ensuring public safety and allowing flexibility in the regulatory environment to accommodate transitional periods for compliance. By providing a mechanism for such consents, the Therapeutic Goods Act 1989 aims to maintain the availability of necessary therapeutic goods while progressively implementing new regulatory standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a broad range of products such as medicines, medical devices, and blood. It is administered by the Therapeutic Goods Administration (TGA) under the auspices of the Commonwealth of Australia's Department of Health. This Act primarily governs the import, export, supply, and sponsorship of therapeutic goods in Australia. It applies to entities and individuals involved in the manufacture, supply, and distribution of therapeutic goods, including pharmaceutical companies, medical device manufacturers, and healthcare providers. The Act's jurisdictional reach is national, extending its regulatory framework across all states and territories in Australia. Notably, the Act provides mechanisms for the issuance of exemptions and the establishment of thresholds, which can be further detailed through subordinate instruments. In the specific case highlighted, a consent was granted under sections 14 and 14A of the Act, allowing the importation and supply of certain pharmaceutical products that do not fully comply with the updated label requirements, but only for specified batches and until a defined date, subject to certain conditions.

Key Provisions

The Therapeutic Goods Act 1989, under sections 14 and 14A, allows for specific consents to be granted in certain circumstances. In this instance, sections 14 and 14A were utilised by a delegate of the Secretary of the Department of Health, on the application of Generic Health Pty Ltd, to permit the importation and supply of particular batches of pharmaceutical products. These products include PHARMACY ACTION HAYFEVER & SINUS PAIN RELIEF, HEARTBURN RELIEF pantoprazole, and PHARMACY ACTION PARACETAMOL PLUS CODEINE tablets. The consent is contingent upon the products not meeting the label requirements stipulated in paragraph 3(2)(g) of the Therapeutic Goods Order No. 69, specifically concerning new warning statements introduced by a legislative instrument from 12 December 2015. This consent is limited to the batches explicitly listed in the application and is valid only until 30 June 2017. Under this consent, Generic Health Pty Ltd is required to use labels for the specified products that were previously approved by the Therapeutic Goods Administration (TGA). These labels must be the same as those provided in the application, and they must be applied to the designated batches. The consent also stipulates that the products must comply with all other relevant requirements under the Therapeutic Goods Act 1989 and associated regulations, except for the specific label requirements mentioned above. The Therapeutic Goods Act 1989 imposes several obligations on parties involved in the importation and supply of therapeutic goods. These obligations include ensuring that products meet all applicable standards and requirements, which encompass labelling, quality, safety, and efficacy. Additionally, entities must adhere to any conditions imposed by the Secretary of the Department of Health when consent is granted under sections 14 and 14A. This includes using labels that have been previously approved by the TGA and ensuring these labels are correctly applied to the specified product batches. Failure to comply with the conditions of consent granted under sections 14 and 14A of the Therapeutic Goods Act 1989, or any other obligations under the Act, may result in various consequences. These can include civil penalties, such as fines, and criminal penalties, including imprisonment, depending on the severity and nature of the breach. The specific penalties are determined based on the provisions of the Act and can vary significantly. For example, supplying a therapeutic good that does not comply with the Act may result in a civil penalty of up to $222,200 for a corporation and $44,440 for an individual, as well as potential criminal penalties. Ensuring compliance with the Act is therefore crucial to avoid these severe repercussions.